Article: Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus.

SAN DIEGO, May 30 /PRNewswire/ -- Gen-Probe Incorporated (NASDAQ: GPRO) announced today that the Company has launched in Europe its APTIMA(R) HPV Assay, a highly specific molecular diagnostic test to detect high-risk strains of the human papillomavirus (HPV), which causes cervical cancer. The APTIMA HPV Assay has been CE marked and is currently available for sale in 13 European Union countries.

"The CE marking and launch of our APTIMA HPV Assay in Europe reflect Gen-Probe's commitment to the development of novel, more accurate molecular diagnostic tests to detect life-threatening infectious diseases such as cervical cancer," said Carl Hull, Gen-Probe's president and ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!